Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors 1,2 . For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential 3 . There is limited intratumoural infiltration of immune cells 4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations 5 . Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-polyl-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8
, Cedrik M. Britten 2, 5, 23 , David Capper 6, 7, 24 , Marij J. P. Welters 5, 11 , Juan Sahuquillo For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential 3 . There is limited intratumoural infiltration of immune cells 4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations 5 . Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-polyl-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8
+ T cells. APVAC2 induced predominantly CD4
+ T cell responses of T helper 1 type against predicted neoepitopes.
Targeting of selected neoepitopes by vaccination in melanoma-a tumour type that has many mutations-has demonstrated high immunogenicity and signs of clinical efficacy 6, 7 . However, only a minority of mutations is processed to HLA-presented neoepitopes that can be targeted by T cells [8] [9] [10] . For cancers with few mutations, this is likely to be a limitation for antigen-unspecific immunotherapies, such as checkpoint inhibitors, as these tumours may frequently lack sufficient amounts of targetable neoepitopes. Nonetheless, clinical and radiographic responses to checkpoint inhibitors have been observed in patients with glioblastoma that had a hypermutation phenotype 11, 12 , suggesting that glioblastoma is in principle susceptible to immunotherapy 13 . T cell responses to unmutated, overpresented antigens have similarly demonstrated encouraging clinical data in glioblastoma [14] [15] [16] and may perfectly supplement the targeting of neoepitopes to achieve broad anti-tumour responses.
To establish a warehouse of premanufactured, synthetic peptides directly available for 'off-the-shelf ' formulation, unmutated HLA-presented antigens were identified from 30 glioblastoma specimens using the XPRESIDENT technology 17 ; preferred antigens were either frequently overpresented 18 or tumour-exclusive, but with low prevalence on tumours. Finally, 33 HLA-A*02:01-binding and 26 HLA-A*24:02-binding peptides (predominantly 9 amino acids; Supplementary Table 1) were selected into the warehouse, favouring candidates with good immunogenicity (see Methods). To address for every GAPVAC-101 patient the relevance of each warehouse peptide as a tumour antigen, the HLA immunopeptidomes and transcriptomes of each individual tumour were characterized by mass spectrometry and microarray analysis, respectively (Fig. 1) . Pre-vaccine T cell reactivity completed the dataset that was used to generate a patient-specific ranking of the warehouse peptides (Extended Data Fig. 1a-d) . As an example, the peptide PTP-013 ranked high for patient 5: it showed tumour-specific overpresentation (Extended Data Fig. 1b ) and mRNA overexpression of the source gene (Extended Data Fig. 1c ). Pre-vaccination peripheral blood mononuclear cells (PBMCs) of patient 5 contained CD8 + T cells that were specific to PTP-013-a prerequisite for a later immune response (Extended Data Fig. 1d ). Actively Personalized Vaccines 1 (APVAC1) were then composed of the seven best-ranking HLA class I peptides, two peptides binding promiscuously to different HLA-DR (class II) molecules ('pan-DR' antigens) and a viral marker peptide (Extended Data Fig. 2a ). All APVAC1 compositions were different Letter reSeArCH (n = 16; Supplementary Table 2) , also illustrated by the selection frequencies of HLA-A*02:01 warehouse peptides for HLA-A*02:01 + patients (n = 13; Extended Data Fig. 1e ), supporting the warehouse concept for personalization. Median definition time from enrolment to start of APVAC1 manufacturing was 52 (range 42-74) days, and median production time until release of APVAC1 was 41 (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) days, enabling the planned vaccination start during the first maintenance temozolomide (TMZ) cycle.
For APVAC2, one of the following strategies was applied to select two peptides for good manufacturing practice (GMP) synthesis and to formulate the vaccine (Extended Data Figs. 1f, 2a ). In the first strategy, mutation-containing peptides were confirmed as HLA ligands by mass spectrometry. In the second strategy, mutation-containing peptides with a predicted high likelihood for HLA class I binding and immunogenicity (usually peptides with a length of 19 amino acids with the mutation at position 10) were used; however, these were not confirmed by mass spectrometry to be HLA ligands. Finally, if neither of the two strategies identified suitable neoepitopes, unmutated glioblastoma-associated HLA class I epitopes that were identified in the individual immunopeptidome, but that were not part of the APVAC1 warehouse, were selected (9 to 10 amino acids). A median of 36 (19- Fig. 1 | GAPVAC concept of active personalization. Unmutated antigens (APVAC1) and preferentially mutated, de novo antigens (APVAC2) were targeted. Vaccinations (triangles) in the GAPVAC-101 trial are superimposed on standard chemoradiotherapy (CRT) and maintenance TMZ cycles (T). Several pretreatment biomarkers and immune response data were evaluated. The soluble HLA (sHLA) analysis has previously been described 27 . GBM, glioblastoma. Letter reSeArCH sequencing within the analysed glioblastoma specimens from GAPVAC-101 patients (Table 1 and Supplementary Table 3 ). None of these 643 genomic mutations was identified in the HLA class I and II peptidomes of the respective patients (n = 15) by high-sensitivity mass spectrometry, whereas the same process identified a mutated HLA-presented peptide in another patient with hypermutated glioblastoma, but who did not participate in GAPVAC-101 (data not shown). Consequently, the selection of the two APVAC2 peptides was based on the second and third strategies presented above, preferring predicted, mutation-containing neoepitopes (Extended Data Fig. 1g ). Eleven patients received APVAC2 compositions with a total of 20 de novo synthesized peptides (14 mutated and 6 unmutated; Extended Data Fig. 1h and Supplementary Table 4) . Median definition time for APVAC2 was 96 (85-114) days and median production time was 86 (63-138) days.
APVAC1 and APVAC2 were applied independently by intradermal injections during TMZ maintenance therapy to HLA-A*02:01 + or HLA-A*24:02 + patients with newly diagnosed glioblastoma following gross total resection and standard chemoradiotherapy with TMZ (see Extended Data Fig. 2b for a detailed vaccination schedule). Granulocyte-macrophage colony-stimulating factor (GM-CSF) (intradermal injection) and poly-ICLC (subcutaneous injection) were coapplied as adjuvants and may enhance immune responses in a synergistic manner 19 . Clinical trial authorization (NCT02149225) was obtained in five European countries based on a standardized drug definition and GMP manufacturing process, leading to variable vaccine compositions for each patient (Extended Data Fig. 9c ) and potentially serving as a model for future trials.
Primary end points were safety, tolerability, immunogenicity and operational feasibility of the concept. Of 58 screened patients (Extended Data Fig. 2e ), 33 failed eligibility criteria and nine were not enrolled owing to limitations to the capacity of GMP production of peptides (1-2 patients per month). Sixteen patients were enrolled before entering chemoradiotherapy. Baseline characteristics of these patients reflect a standard population of patients with glioblastoma (Table 1) . Fifteen patients received APVAC1 (median: 12 applications) and eleven patients received APVAC2 (median: 10 applications; Extended Data Fig. 2c ).
All vaccinated patients experienced adverse events related to the drugs used in the study (Supplementary Table 5 ) that were within expectations. Mild-to-moderate injection site disorders were most frequent, consistent with the expected mechanism of action of the vaccinations. Eleven patients experienced adverse events of at least grade 3, mainly bone marrow suppression, which is frequently observed in patients who undergo chemoradiotherapy with TMZ. Two patients experienced an anaphylactic reaction after receiving vaccinations, Letter reSeArCH potentially related to repeated application of GM-CSF 20 . Patient 9 required high-dose steroid treatment owing to potentially immuneassociated grade 3 brain oedema.
Ex vivo multimer analysis revealed vaccine-induced CD8 + T cell responses to at least one APVAC1 HLA class I peptide in 12 out of 13 patients (92.3%; median: 3 responses; Fig. 2a ). These responses usually persisted for several months. The presence of specific precursor T cells in the blood of the patients was a strong selection criterion for APVAC1. Consequently, APVAC1-reactive T cells were frequently observed pre-vaccination, usually at a low frequency and with a naive phenotype. After vaccination, APVAC1-specific T cells shifted to a memory phenotype and in most cases showed an increased frequency (Fig. 2b) . For single specificities, the magnitude of ex vivo measured CD8 + T cell responses was up to 0.02% of CD8 + T cells. The increase in expression of programmed cell death protein 1 (PD-1) was low to moderate, which is indicative of T cells that do not have an exhausted phenotype (Extended Data Fig. 3a, b Table 2) .
APVAC1-induced PTP-013-reactive CD8 + T cells cloned from post-vaccination PBMCs of patient 16 (PTP T cells) killed peptideloaded K562-A2 target cells with high avidity (Fig. 2c and Extended Data Fig. 3d ). These T cells also lysed the glioblastoma cell line L2 (Fig. 2d) , which endogenously expresses the source gene of PTP-013 (PTPRZ1), demonstrating the functional capacities of APVAC1-induced T cells and the natural HLA presentation of PTP-013. The dominant NLGN4X-001-specific T cell receptor (TCR) from the same patient was cloned and re-expressed in PBMCs from a healthy donor. T cells transfected with this TCR (NLGN4X T cells) showed cytotoxicity against the cells of the NLGN4X + glioblastoma cell lines L2 (Fig. 2e ) and P3XX (Extended Data Fig. 3e ), whereas the cells of NLGN4X − glioblastoma cell line U87MG were only killed after transfection with NLGN4X (Extended Data Fig. 3f, g ). In total, 9 out of 13 patients (69.2%) showed CD4 + T cell responses to one or both unmutated pan-DR antigens in APVAC1 (ex vivo intracellular cytokine staining (ICS); example shown in Fig. 2f ) with an overall immunogenicity of 50% for these peptides (Fig. 3) . The responding T cells were of a heterogeneous phenotype, but frequently T helper type 1 (T H 1) cells (Figs. 2a, 3 ). The ratio of cumulative APVAC1-specific CD8 + memory T cell frequencies post-compared to pre-vaccination for a patient was defined as the memory cell induction factor (MCIF) (Fig. 2a) . The MCIF was higher in patients who lacked a predominant T H 2 or suppressive CD4 + T cell response to APVAC1 (Extended Data Fig. 4d ). Frequencies of regulatory T (T reg ) cell pre-vaccination (Extended Data Fig. 4a) were predictive of the biological activity of APVAC1. Low levels of T reg cells were found in patients with a MCIF above median and were associated with a higher proportion of interferon-γ (IFNγ)-producing APVAC1-specific CD4
+ T cells (Extended Data Fig. 4e , f).
Eight out of ten patients (80%) who were evaluable for APVAC2 immunogenicity developed neoepitope-specific, dominantly CD4 + T cell responses (pan-ICS assay after in vitro sensitization; Extended Data Fig. 4h ). In total, 11 out of 13 (84.7%) vaccinated, mutated APVAC2 peptides induced a CD4
+ T cell response (Figs. 3, 4a). These responses had predominantly a T H 1 phenotype and were multifunctional (Fig. 3 ). For two neoepitope-specific CD4 + T cell responses, recognition of the corresponding wild-type sequences was tested, which revealed that one response showed cross-recognition and the other neoepitope specificity (Extended Data Fig. 7a ), consistent with the broad spectrum of wild-type cross-recognition that has previously been reported 6 . Five neoepitope-specific CD4 + T cell responses came with CD8
+ T cell responses to nested, mutated HLA class I-restricted epitopes ( Fig. 4b and Extended Data Fig. 4h ). None of the mutated APVAC2 peptides evoked an isolated CD8 + T cell response. Notably, the 14-M09-specific CD8 + T cell response measured by pan-ICS was confirmed by ex vivo multimer staining using a predicted, mutated HLA-A*02:01 ligand that was contained in the 19 amino acid-long peptide (Fig. 4c) . Figure 3 displays the favourable immunogenicity that was observed for GAPVAC-101. For the six unmutated antigens within APVAC2, an immune response was observed only once (patient 8). These antigens were immunized without prior knowledge about their immunogenicity (in contrast to APVAC1 peptides), arguing for the importance of immunogenicity as a selection criterion for HLA class I antigens.
Tumour-infiltrating lymphocytes (TILs) were isolated and cultured for all but one patient at initial surgery, applying a harmonized TIL isolation and expansion protocol for glioblastoma specimens (see Methods). Expanded TILs comprised CD4 + and CD8 + T cells (Extended Data Fig. 8a-c) . Analysis of TCR clonotypes in tumours and corresponding expanded TIL cultures (n = 3) revealed relatively few amplified TCR clonotypes in glioma tissue, consistent with recent flow cytometry-based data 21 but in contrast to previous observations for TILs in other tumour types 22, 23 . Notably, even fewer TCR clonotypes expanded in vitro (Extended Data Fig. 8d ). No reactivity against any single APVAC was detected in any pre-vaccination TIL cultures from GAPVAC-101 patients or other patients with glioblastoma (n = 30 total, data not shown), suggesting that spontaneous T cell immunity against glioblastoma is rare but may be inducible by vaccination.
Some centrally confirmed radiographic responses were reported (Fig. 5a ). However, in the months after chemoradiotherapy and maintenance TMZ such changes are seen frequently. Patients that received vaccinations (n = 15) had a median overall survival of 29.0 months from diagnosis and a median progression-free survival (PFS) of Table 1 ). Patient 8, who had a resolved pseudo-progression and an overall survival of >38.9 months experienced a favourable immune response pattern, with CD8 + T cell responses to five APVAC1 class I peptides, T H 1 CD4 + T cell responses to both APVAC1 pan-DR peptides, and a combined CD8 + and T H 1 CD4 + T cell response to an APVAC2 neoepitope. The tumour was re-resected upon recurrence 26.8 months after diagnosis and demonstrated high infiltration by T cells with a favourable CD8 + T/FOXP3 + T reg cell ratio (Fig. 5b) . The tumour contained CD4 + T cells directed against the APVAC1 pan-DR peptide PTP-010 (Fig. 5c ), corresponding to multifunctional, T H 1-dominated reactivity in the periphery (Fig. 5d) .
The warehouse-based APVAC1 process resulted in truly individual drug compositions, justifying the complex personalization. Failure to identify any of the 643 genomic mutations in the HLA peptidome of the patients may be due in part to the limited sensitivity of the mass spectrometry approach. However, rates below 1% were reported previously for the transition of mutations into HLA class I ligands 9, 24 , suggesting that the GAPVAC-101 data may partially reflect high attrition of mutations from the genetic level to actual HLA presentation of mutated peptides. This hypothesis is supported by the finding that during immunological validation of mutations, TILs were found to be reactive against only 1.2% of mutations 25 . Notably, the same mass spectrometry approach as applied here was able to identify mutated HLA ligands in human tumour tissue. With the uncertainty of neoepitope predictions, targeting of a higher number of mutations-if not all-would be favourable 8 . For glioblastoma and other tumour types that have low numbers of mutations, additional exploitation of the unmutated antigen pool is justified, and our personalized warehouse-based peptide vaccine approach was shown to be well-suited to address these antigens.
General superiority of neoepitopes to induce CD8 + T cell responses versus unmutated class I peptides was not observed (Fig. 3) , although data must be compared with caution since the peptide format, analysis methodology and availability of immunogenicity pretesting differed between APVAC1 and APVAC2. Our CD8 + T cell reactivity compared favourably with previous trials and particularly with responses seen with a vaccine that shared several antigens with the GAPVAC warehouse 16 (Extended Data Fig. 4g ). Improved immunogenicity may be attributable to the immune modulators, poly-ICLC plus GM-CSF (GAPVAC-101) versus GM-CSF alone (previous trial). Nevertheless, immune response induction needs further optimization.
The ACT IV trial, which tested rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma and had similar eligibility criteria, demonstrated a median overall survival of 20 months 26 and may come closest to a reference cohort, to which the median overall survival of 29 months of the GAPVAC-101 trial compares favourably with all limitations of comparing small early phase trials to phase III trials. Further efforts are required to decrease process complexity and duration, but the achievements of the current trial certainly warrant further studies to understand how anti-tumour immunity can be leveraged to ultimately achieve clinical benefit for patients with glioblastoma. 17, 28 . From this repertoire, strongly tumour-associated candidates were identified-that is, peptides that were exclusively found on tumours or were highly overpresented compared to the immunopeptidome of a panel of normal tissue types. Expression analyses of mRNAs from source genes of glioblastoma samples in comparison to expression in normal tissue and immunogenicity analysis of the blood of healthy donors was used as supportive data to select for 33 HLA-A*02:01 and 26 HLA-A*24:02 warehouse peptides (Supplementary Table 1 + patients with newly diagnosed glioblastoma after gross total resection as judged by a post-operative scan within 48 h post-surgery, Karnofsky performance score of ≥70% and a life expectancy of over six months were enrolled (see clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT02149225?cond= GAPVAC&rank=1) for details on eligibility criteria). From the initial surgery, a tumour tissue specimen was freshly frozen for later immunopeptidome, mRNA expression and mutanome analysis. If possible, a further tumour tissue sample was used fresh for isolation of TILs (see 'Functional testing of TILs'). Moreover, plasma samples were collected pre-and post-surgery for analysis of the soluble HLA ligandome 27 . Before the start of standard chemoradiotherapy with TMZ, leukapheresis was performed (target cell yield: 4.8 × 10
9 white blood cells) and PBMCs were isolated for analysis of the immune repertoire of individual patients (see below). APVAC1 and APVAC2 vaccines for each patient were designed and manufactured starting during standard-of-care chemoradiotherapy 29 . Vaccinations with APVAC1 (400 μg per peptide, intradermal, 11 vaccinations scheduled) started on day 15 of the first adjuvant TMZ cycle (see Extended Data Fig. 2b for schedule details). GM-CSF (75 μg, intradermal) and poly-ICLC (1.5 mg, subcutaneous) were used as immune modulators and were applied near the APVAC injection site. APVAC2 vaccines were applied starting on day 15 of the fourth adjuvant TMZ cycle (400 μg per peptide, intradermal, 8 vaccinations scheduled), usually leading to co-application of APVAC1 and APVAC2 at three visits (Fig. 1) . After completion of the regular APVAC vaccinations or after progression, it was possible to continue vaccinations if this was in the patient's best interest and if medication was still available. Continued vaccinations beyond the regular schedule were performed at four-weekly intervals. Nine patients received vaccinations under this 'continued vaccination' option. Exposure to standard therapy was not altered for patients in the GAPVAC-101 trial (Extended Data Fig. 2d ). Primary end points of the trial were safety and tolerability, feasibility of the personalized approach and biological activity. APVAC1 selection and manufacturing. The fresh-frozen tumour samples of patients underwent central pathology review to enrich for necrosis-free tumour pieces with high tumour-cell contents. Tumour-cell-enriched specimens were lysed and HLA class I-and class II-associated peptides were isolated and analysed by mass spectrometry as previously described 17 . In brief, HLA-peptide extracts were separated by reversed-phase chromatography (nanoAcquity UPLC system) using ACQUITY UPLC BEH C18 columns (75 μm × 250 mm, Waters). Mass spectrometry was performed on Orbitrap LTQ Velos or Fusion mass spectrometers (ThermoFisher Scientific) by data-dependent acquisition using collisioninduced dissociation as well as higher-energy collisional dissociation. Furthermore, genomic DNA and mRNA were isolated from the same lysate for mutanome and gene-expression analyses, respectively. mRNA was quality-controlled and analysed by gene microarray analysis using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide microarrays (Affymetrix). Finally, PBMCs of the patient were assessed for precursor T cells that were specific for the APVAC1 peptides as previously described 30 . In brief, CD8
+ T cells were stimulated in vitro under limited dilution conditions (usually 12 wells per peptide) using artificial antigen-presenting cells. Wells with >1% specific CD8
+ T cells as per multimer staining after three weeks of culture were counted as positive. If no individual immunogenicity data were available for the patient (patient 13), the percentage of positive wells in healthy donors was used as surrogate. For each patient, a ranking score was calculated for each warehouse peptide, considering the individual peptide-presentation data, mRNA expression data and immunogenicity data (see Supplementary Methods ' APVAC1 selection process' for details). In brief, the different parameters were transformed into probability scores (values between 0 and 1) using a Bayesian method. The rank score of a warehouse peptide constitutes a probabilistic score that ensured strong tumour association as well as sufficient immunogenicity for highly ranked peptides. For each patient, the seven best-ranked peptides were selected into the personalized APVAC1 composition (as shown for patient 5 in Extended Data Fig. 1a) together with a viral marker peptide (HBV-001 or HCV-002) and BIR-002/PTP-010 as invariant pan-HLA-DR (class II)-binding peptides (PTP-010 was replaced by BCA-005 for two compositions owing to stability issues). Finally, APVAC1 compositions were reviewed and approved by a Target Selection Committee. The peptides were formulated into single-dose vials and released according to GMP at the manufacturing site of the Department of Immunology, University of Tübingen. APVAC2 selection and manufacturing. For APVAC2, tumour-specific somatic mutations were analysed by BioNTech from the DNA and RNA samples extracted from high-quality enriched tumour materials compared to DNA from normal blood cells from the same patient using next-generation sequencing. Whole-exome sequencing libraries were prepared using Agilent's SureSelect V6 XT Kit. From the tumour RNA, poly(A)-based RNA sequencing libraries were prepared using TruSeq (Illumina). For samples with a tumour content above 40%, whole-exome and RNA sequencing libraries were prepared in singletons and sequenced pairedend for 50 nucleotides on an Illumina HiSeq 2500, aiming for a minimum of 150 million reads per library. For samples that had a tumour content below 40%, library preparation and sequencing were done in duplicates. All mutanome-related data analysis steps were coordinated by a software pipeline. For the DNA libraries, a minimum of 150 × 10 6 paired-end 50-nucleotide reads and for the RNA libraries a minimum of 75 × 10 6 paired-end 50-nucleotide reads were required. For mutation detection, DNA reads were aligned to the reference genome hg19 with BWA 31 . Exomes from tumour and matched normal samples were analysed for singlenucleotide variants. Loci with putative homozygous genotypes in the normal samples were identified and filtered to retain high-confidence calls for single-nucleotide variants. The remaining sites were further inspected for a putative homozygous or heterozygous mutational event. Suspected sites were filtered to remove potential false positives. The final list of single-nucleotide variants consisted of high-confidence homozygous sites in the normal samples and high-confidence heterozygous or homozygous mutational events in the tumour samples. Genomic coordinates of identified variants were compared with known transcript coordinates for genes of the University of California Santa Cruz (UCSC) at https://github.com/brentp/ cruzdb to associate the variants with genes, transcripts, potential changes in amino acid sequences and the RNA-sequencing-derived expression values. For RNAsequencing analyses, RNA reads were aligned to the hg19 reference genome and transcriptome using Bowtie 32 , and gene expression was determined by comparison with known transcript and exon coordinates of genes of the UCSC, followed by normalization to reads per kilobase million (RPKM) units 33 . High-sensitivity liquid chromatography-tandem mass spectrometry data were analysed against a personalized proteome library that contained all single-nucleotide variants to identify HLA class I-and class II-presented, mutation-containing peptides. Mass spectrometryconfirmed mutations containing HLA epitopes would have gained priority for APVAC2 (but were not detected). As a second track, predicted variants were selected from the identified single-nucleotide variants by first removing non-sense variants and filtering by non-zero exon and transcript expression and then sorting by exon expression followed by HLA class I-binding prediction score using a stable sorting algorithm. HLA-binding affinity was predicted via the Immune Epitope Database (IEDB) T cell prediction tools (version 2.5, IEDB-recommended mode) 34 using all variant-containing 8-11 amino acid-containing peptides for HLA-A/Bbinding estimations. Out of all predictions for a single variant, the best IEDB consensus score was associated with the respective variants. Potential immunogenicity was assessed by calculating the difference between the predicted HLA-binding affinity of the mutant peptide and the wild-type counterpart as well as absolute predicted HLA binding and variant expression, by analogy with a previously published algorithm 35 . A shortlist of up to 46 single-nucleotide variants was selected for confirmation by Sanger sequencing. For primer design, genomic sequences that flanked the mutation sites were extracted from the reference genome and used as input for the Primer3 software 36, 37 . The output primer pairs were aligned to the reference genome using BLAT 38 . Primer pairs that aligned to off-target loci were removed, and the remaining optimal primer pair was returned for each input site. Sanger sequencing was performed by amplifying each selected mutated locus from DNA of tumour tissues and white blood cells by PCR (15 min at 95 °C for the initial activation followed by 35 cycles of 30 s at 94 °C for denaturation, 30 s at 60 °C for annealing, 30 s at 72 °C for extension, and 6 min at 72 °C for the final extension). Each PCR product was quality-controlled using a QIAxcel (Qiagen) device and purified via ExoI/AP treatment. Sanger sequencing was performed by Eurofins/ MWG. From the confirmed mutations, only the highest-ranking ones as judged by HLA binding, expression and immunogenicity were considered for APVAC2 as 19 amino acid peptides (mutation flanked by 9 amino acids of the natural sequence on each side to cover all potential mutation-containing HLA-binding 9-10 amino acid peptides, while minimizing the number of contained potential HLA binders that do not contain the mutation). As a third track, HLA class I peptidome data were assessed for tumour-associated unmutated peptides not contained in the warehouse. Highly promising candidates were integrated into the prioritized ranking (without immunogenicity pretesting). The Target Selection Committee selected the most promising candidates from all APVAC2 tracks to a ranked shortlist with up to four candidates. The final selection also considered variant allele frequency, tissue distribution of wild-type source gene expression and confirmation of mutations by Sanger sequencing. Manufacturability of the four candidates was tested under non-GMP conditions. If successful, the two highest-ranking APVAC2 peptides were de novo synthesized, formulated under GMP conditions and filled into single-use vials at the manufacturing site of the Department of Immunology, University of Tübingen. For patients 1, 2, 6, 12 and 15, low yield and/or purity of an APVAC2 peptide candidate required replacement by backup candidates or removal of one peptide (patients 6 and 12). For patient 6, first application of APVAC2 was delayed by one TMZ cycle owing to delays in manufacturing. In all other cases, GMP manufacturing of APVAC2 was completed in time. Clinical assessments and feasibility assessment. Safety in this trial was analysed based on the occurrence of adverse events, which were categorized according to the US National Cancer Institute's Common Terminology Criteria for adverse events version 4.0 and summarized on the preferred term level of the Medical Dictionary for Regulatory Activities version 18.0 and according to their potential relation to study drugs (APVAC vaccines, GM-CSF or poly-ICLC) and TMZ treatment. Operational feasibility was assessed based on success rates and duration of APVAC1 and APVAC2 definition and manufacturing processes. Magnetic resonance imaging scans were taken according to European Society of Medical Oncology guidelines 39 and evaluated based on the criteria defined by the NeuroOncology Working Group 40 , taking special care in the aspect of potential pseudoprogression, which may be frequent in immunotherapy trials owing to immune cell infiltration into the glioblastoma tumour 14 .
Immune response assessment and biomarker analyses. At different time points pre-and post-vaccination (Fig. 1) , PBMCs for immunomonitoring were isolated within 8 h of venipuncture from sodium heparin blood samples of patients by standard Ficoll-Hypaque density gradient centrifugation. Cells were cryopreserved in serum-free medium until standardized assessment of immune responses (Immatics). Thawed PBMC samples were labelled with CD8 microbeads (Milteny Biotec) and the CD8 + T cell fraction was separated from CD8 − cells by MultiMACS device according to the manufacturer's instructions. Both cell fractions were rested overnight. HLA class I ex vivo 2D multimer assay. Ultraviolet exchange was used to create peptide:MHC (pMHC) monomers loaded with specific APVAC peptides as previously described 41 . An anti-β2-microglobulin enzyme-linked immunosorbent assay (ELISA) was performed to confirm the efficiency of peptide exchange.
For each peptide to be tested, two pMHC multimers of the same specificity but with two different fluorochromes were combined as previously described 42 . All APVAC and control pMHC multimer solutions for a given patient were combined to one personalized pMHC multimer staining cocktail. Potential aggregates were removed by centrifugation. Staining was performed as previously described 43 . In brief, between 1.5 × 10 6 and 5 × 10 6 CD8 + T cells were treated first with Life/ Dead near-infrared dye (Life Technologies), followed by patient-individual 2D multimer staining 18 (each pMHC multimer at a concentration of 1-5 μg ml
) and surface staining with the following antibodies: CD8-fluorescein isothiocyanate (FITC; SK1, BioLegend), CD279/PD-1-BV786 (EH12.1, BD); CD197/CCR7-phycoerythrin (PE)-CF594 (150503, BD); CD45RA-AF700 (HI100, BioLegend) and CD4 (RPA-T4, BD), CD14 (61D3, ebioscience), CD16 (3G8, BD) and CD19 (HIB19, BD) antibodies for dump channel (all PE-Cy5). All washing steps were carried out in phosphate-buffered saline (PBS), 2% fetal calf serum (FCS), 2 mM ethylenediaminetetraacetic acid (EDTA) and 0.01% azide. Stained cells, fixed with FACS Perm2 solution (BD), were acquired on a LSRII SORP flow cytometer (BD) and analysed by FlowJo software version 10.1 (Tree Star). Two-dimensional multimer-positive cells had to be positive for the corresponding fluorochrome combination, but negative for any other fluorochrome as determined by Boolean gating 42 . The gating strategy is shown in Extended Data Fig. 10a . The presence of a vaccine-induced response was determined according to predefined criteria 43 .
In brief, frequencies of 2D multimer-positive cells among CD8
+ T cells had to be at least twofold above the corresponding frequency before vaccination and had to form a clustered population that was discrete from multimer-negative cells. Staining against viral control antigens was performed for each donor. Influenzaderived peptide FLUM-001 (GILGFVFTL, HLA-A*02) and/or Epstein-Barr virus (EBV)-derived peptide EBV-014 (TYSAGIVQI, HLA-A*24) were used as positive controls; human immunodeficiency virus (HIV)-derived peptides HIV-001 (ILKEPVHGV, HLA-A*02) and/or HIV-015 (RYPLTFGW, HLA-A*24) were used as negative controls. Viral marker peptides (HBV-001 or HCV-002) were co-vaccinated in APVAC1 and used as vaccination controls 44, 45 . For each stain experiment, two healthy donors (one HLA-A*02 phenotypes was calculated per assay time point. In cases in which no event was detected, 0.1 event per antigen specificity was assumed. Next, the ratios of these memory cell frequencies post-vaccination versus pre-vaccination were calculated for each post-vaccination time point. The MCIF for a patient was defined as the maximum of these ratios. For patient 4, BCA-002-and PLEKHA4-001-reactive T cells were present before vaccination and did not expand, resulting in a low MCIF despite high frequencies (Fig. 2a) . Ex vivo HLA class II ICS assay. After overnight rest, between 1.7 and 5.1 × 10 6
CD8
− T cells per well were incubated with antigenic peptide (10 μg ml
) in the presence of monensin and brefeldin A as per the manufacturer's instructions (both BD) for 6 h at 37 °C. Cells of each assay time point were stimulated with the corresponding APVAC1 class II peptides. Furthermore, cells were stimulated with mock peptide (solvent only) as an internal negative, and a CMV-002 (LPLKMLNIPSINVH)/CEFT peptide pool MHC class II (Panatecs) as a positive, control. Additionally, in each assay two healthy donors were used as external controls and stimulated using mock, HIV-001/HIV-015 as negative and a pool of CMV-002, EBV-014, influenza-derived FLUM-001 (GILGFVFTL) and CEFT peptides as positive controls. After stimulation, CD8
− cells were treated with Life/ Dead near-infrared dye (Life Technologies), followed by surface-staining using a CD8-BV570 (RPA-T8, BioLegend) antibody. After a washing step in PBS, 2% FCS, 2 mM EDTA and 0.01% azide, cells were fixed using FACS Perm2 solution (BD) and intracellular staining was carried out using PermWash (BD) and CD3-BV711 Fig. 10b ). Out of 7 cytokines or markers, all 2 7 = 128 possible combinatorial patterns were calculated using Boolean gating. To be defined as a vaccine-induced response, the frequency of cytokine-positive cells within one combinatorial pattern had to be at least twofold over the frequency in the corresponding mock control and the frequency before vaccination. HLA-class I and class-II pan-ICS assay. PBMC samples were incubated with 0.5 U ml −1 benzonase (Merck). APVAC2-or control peptide-specific CD4 + and CD8 + T cells were amplified by a single round of IVS for 12 days using 2.5 × 10 6
PBMCs per well, 10 μg ml −1 of antigenic peptide and 20 U ml −1 IL-2 (Novartis). Samples of each assay time point of a given patient were stimulated with a pool of all patient-specific full-length APVAC2 peptides as well as separately with a viral peptide pool (containing FLUM-001, CMV-002, EBV-014 and CEFT), which served as a positive control for IVS. As interassay control, two healthy donor controls were included in each individual assay. After 12 days, cells were restimulated (0.275-1.7 × 10 6 cells per well) with 10 μg ml −1 antigen peptide in the presence of monensin, brefeldin A and CD107a-FITC (H4A3, BD) antibody for 6 h at 37 °C. Restimulation was either performed with individual full-length APVAC2 peptides or pools of all possible peptides that were nine amino acids long and predicted HLA class I epitopes that were derived from a given parental APVAC2 peptide (if applicable). Mock peptide control and stimulation with viral peptide pool as positive control were included. Stimulated cells were surface-stained using CD8-BV605 (SK1, BioLegend) before fixation with FACS Perm2 solution (BD). Intracellular staining with antibodies CD4-BV785 (RPA-T4, BioLegend), CD154-BV421 (TRAP1, BD), IFNγ-PE-Cy7 (4S.B3, BD), IL-2-BV510 (MQ1-17H12, BioLegend), IL-5-PE (JES1-39D10, BD), IL-10-BV650 (JES3-9D7, BD), IL-17-BV570 (BL168, BioLegend), IL-21-APC (3A3-N2, BioLegend) and TNF-AF700 (MAb11, BD) was carried out in PermWash buffer (BD). Cells were acquired and analysed as described above to assess cytokine-positive cells among CD4 + and CD8 + T cells. Gating was performed according to recommendations of the CIP (Extended Data Fig. 10c) . Using Boolean gating, 77 out of 512 combinatorial patterns were selected, reflecting the cytokine expression profiles of T H cell subsets as previously described 47 . To be defined as a vaccine-induced response, the Letter reSeArCH frequency of cytokine-positive cells within one combinatorial pattern had to be at least fourfold over the frequency of the corresponding mock control and the frequency before vaccination. IFNγ enzyme-linked immunospot assay. Detailed protocols have previously been described 48, 49 . In brief, for Fig. 5d , PBMCs from patient 8 were thawed and expanded for 12 days in the presence of 5 μg ml −1 peptide and 2 ng ml −1 recombinant human IL-2 (R&D). Cells were collected and tested in duplicates by IFNγ enzyme-linked immunospot assay (ELISPOT) with 2.5 μg ml −1 peptide, 10 μg ml −1 phytohaemagglutinin (PHA)-L as positive control or 10% dimethyl sulfoxide (DMSO) as mock. After 26 h incubation, spots were revealed with 5-bromo-4-chloro-3-indolyl-phosphate/nitro-blue tetrazolium chloride and analysed with an ImmunoSpot Series 6 ELISPOT Reader (C.T.L. Europe). TIL expansion protocol. A harmonized protocol for TIL expansion was established during the preclinical phase of the project. First, information on protocols established at each clinical centre for TIL isolation and in vitro expansion were compared; based on this survey, three IL-2 concentrations (150, 1,000 and 6,000 IU ml
) and the addition of a CD3 signal (soluble CD3 antibody or beads coated with CD3/CD28 antibodies) were tested for expanding glioma TILs. Cell outgrowth, cell yields and distribution of T and natural killer cell subsets were determined for 24 gliomas altogether at four centres. T cell expansion was similar in the presence of 6,000 IU ml −1 and 1,000 IU ml −1 IL-2, but lower with 150 IU ml 
TCRαβ
+ cells were prominent in most cultures, which is different when compared to what is found for melanoma (Extended Data Fig. 8a ). In some individual cultures, a stronger expansion of CD8 + T cells was observed (Extended Data Fig. 8c ). Hence, we recommend culturing several individual cultures rather than pooling all TILs. CD3 stimulation clearly increased cell yield compared to IL-2 alone (Extended Data Fig. 8b ), as previously observed 50 . In 2 out of 2 tumours tested, the CD4
+ T cell ratio did not change significantly over the weeks of culture (three tests at one-week intervals, data not shown). On the basis of the results obtained in these optimization experiments, a concentration of recombinant human IL-2 of 1,000 IU ml −1 and the addition of a CD3 antibody were finally chosen. The final GAPVAC harmonized protocol for glioblastoma TIL expansion, which was afterwards applied during the clinical phase is provided in the Supplementary Methods (see 'Harmonized GAPVAC TIL isolation and expansion protocol from glioblastoma tumour specimens'). Functional testing of TILs. TIL peptide-specificity testing was performed using ICS (for HLA class I peptides and HLA class II or long peptides) and HLAmultimer staining (for HLA class I peptides only). Both assays were harmonized during the preclinical phase by organizing successive proficiency panels (n = 4 in total) based on those published by the Immunoguiding programme of the Association for Cancer Immunotherapy (CIP-CIMT) 46 , 51, 52 . For Fig. 5c , TILs were thawed, counted and allowed to rest in the presence of 1 μg ml −1 DNAse I. Cells were then washed and stimulated with peptides (10 μg ml 
. Immunohistochemistry. The mouse monoclonal antibodies CD8 (clone C8/144B; DAKO) and FOXP3 (clone 236A/E7; Abcam), and the rabbit monoclonal antibody granzyme B (rb-poly; Abcam) were used in combination with Bright Vision anti-mouse antibody (Immunologic) or Bright Vision anti-rabbit antibody (Immunologic), respectively. After deparaffinization, sections were immersed into 100% ethanol (2×), 96% ethanol (2×) and 70% ethanol (2×), incubated at 120 °C for 10 min in citrate buffer (pH 6) for epitope retrieval and allowed to cool to room temperature. After quenching and blocking, the slides were incubated overnight with the first antibody followed by incubating with the second antibody for 30 min and substrate reaction using Vector NovaRED (Vector Laboratories). Cells were counterstained with Mayer's haematoxylin. Positive control slides (stomach and tonsil) without the primary antibody were included in all assays. The exact number of positive lymphocytes per mm 2 tumour tissue was evaluated after manual spot recognition by Definiens-Tissue Studio software analysis. Positive cells from four representative areas within the tumour tissue were evaluated. TCR clonotype analysis. RNA was isolated from tumour specimens and TIL cultures using the NucleoSpin RNA kit (MACHEREY-NAGEL) according to the manufacturer's instructions. RNA was reverse-transcribed to complementary DNA (cDNA) using the SuperScript VILO cDNA Synthesis Kit (ThermoFisher Scientific). TCR clonotype mapping was carried out as previously described 53 .
In brief, cDNA was amplified by PCR using a primer panel that amplified the 24 β-chain variable (BV) region families of the TCR in DNA fragments suitable for TCR clonotype mapping by electrophoresis on a denaturing gradient gel that contained 6% polyacrylamide and a gradient of urea (Sigma Life Science, Sigma-Aldrich) and formamide (Sigma-Aldrich) from 20% to 80%. Gels were run at 160-175 V for 4.5 h in TAE (0.04 M Tris-acetate and 0.001 M EDTA) and kept constantly at 56 °C. Gels were stained with cyber green and visualized under ultraviolet light. TCR identification and in vitro expansion. APVAC1-specific T cells were sorted from post-vaccination PBMCs of patient 16. TCR sequences were obtained by single-cell rapid amplification of cDNA-end (RACE) PCR and subsequent sequencing of the α and β chains 54 . In parallel, sorted T cells were stimulated in vitro for three weeks using PHA (2 μg ml ) and were subsequently used in Vital-FR killing assays. TCR cloning. The VDJ regions of the TCR were combined in silico with mouse constant regions modified to include an additional disulfide bond, as previously described 55 . The α and β human/mouse chimeric TCR chains were codonoptimized in silico and linked by a furin cleavage site and P2A sequence to form a polycistronic transcript. Constructs were synthesized by ThermoFisher Scientific or Eurofins Genomics, before being cloned downstream of an EF1A (also known as EEF1A1) promoter in a mammalian transient expression vector using golden gate assembly. Cloning of overexpression constructs. cDNA of NLGN4X in a pDONR vector was provided by R. Will of the DKFZ GPCF Vector and Clone Repository. An internal ribosomal entry site (IRES) sequence was appended to the NanoLuc luciferase sequence using tailed primer PCR, and the resulting PCR product was inserted into pDONR P2rP3 using Gateway BP cloning. The phosphoglycerate kinase 1 (PGK1) promoter was inserted into pDONR P4-P1r using tailed primer PCR and Gateway BP cloning. Expression vectors that combined the PGK1 promoter, the full-length cDNA of NLGN4X or NRCAM, and the IRES-NanoLuc luciferase marker were assembled using Multisite Gateway LR cloning.
Electroporation of T cells and transfection of target cells. T cells were isolated from PBMCs from HLA-A2*01
+ healthy donors using the MagniSort Human T cell Enrichment Kit according to the manufacturer's instructions. T cells were kept in TexMACS without phenol red and activated with 155 U ml −1 human IL-7, 290 U ml −1 human IL-15 and T Cell TransAct. Vector DNA was prepared using a ZymoPURE II plasmid maxiprep kit (Zymo Research). Plasmid DNA was electroporated using a Neon electroporator (ThermoFisher Scientific; pulse voltage 2,200 V, pulse width 20 ms, pulse number = 1, cell density = 5 × 10 6 ). Transfection of HLA-A*02:01 + U87MG cells was done using FuGENE HD (Promega). Cytotoxicity assays. Avidity of APVAC1-specific T cells as shown in Fig. 2c was analysed using the Vital-FR assay 56 . In brief, T cells were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labelled K562-A2 cells loaded with titrated amounts of test peptide and FarRed-labelled K562-A2 cells loaded with an irrelevant peptide. After 20 h, numbers of CFSE-and FarRed-labelled cells were assessed by flow cytometry and specific lysis was calculated. For peptide titration experiments (Extended Data Fig. 3d ), T2 cells were stained with Vybrant DiD and T cell clones with CFSE. Co-culture (4 h) was performed with increasing concentrations of peptide (effector-to-target ratio (E:T) = 10:1). Cell death was measured by addition of 7-aminoactinomycin D (7AAD) and detection of 7AAD + Vybrant DiD + T2 cells by flow cytometry. For NanoLuc luciferase-based killing assays, TCR-engineered T cells and transfected U87MG target cells (NLGN4X and NRCAM) were cocultured for 9 h. Supernatants were carefully removed to remove cell debris. After addition of new medium, the Nano-Glo Luciferase Assay System (Promega) was used according to the manufacturer's instructions to measure NanoLuc luciferase expression. For LDH-based killing assays, autologous (NLGN4X-001-reactive, PTP-013-reactive) and HLA-A*02:01 + T cells were rested overnight and co-cultured for 9 h with HLA-A2*01
+ glioma-initiating cell lines (L2 or P3XX). A CytoTox96 Non-Radioactive Cytotoxicity Assay (Promega) was used according to the manufacturer's instructions to quantify LDH release. Absorbance was measured at 490 nm. Cell lines are tested monthly for the absence of mycoplasma. Cell line authentication is ensured by genetic testing using Gene Print (Promega). At least 500,000 events were acquired per sample. Gating and enumeration of T reg cells was based on CD25, CD127 and FOXP3 expression (Extended Data Fig. 10d ), as previously described 57 . Statistical analyses. Clinical data collection and management was carried out using SAS (v.9.3; SAS Institute). Where applicable, data were reported as the median (indicating the range from minimum to maximum value occurred) and arithmetic mean ± s.d., as specified (R software package v.3.4.1). Dichotomous variables were evaluated by Fisher's exact test, whereas continuous variables were compared by two-sided Student's t-test or Mann-Whitney U-test, as indicated. Overall and progression-free survival (both calculated from primary tumour diagnosis) were assessed by Kaplan-Meier analysis using Prism 7 (GraphPad Software). An independent data safety monitoring board oversaw the study. Patient PBMCs were limited in this study. If not stated otherwise, and owing to limited sample availability, immune response assessments could only be performed once and were not repeated. As detailed in the sections for ex vivo 2D multimer, ex vivo ICS and pan-ICS analyses, various internal and external controls were included and per assay type, all patient assays were done with the same batches of critical reagents (for example, staining antibodies). Furthermore, all patient assays were performed according to detailed standard operating procedures. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Raw data that support the findings of this study shown in Figs Table 1 and Supplementary Table 5 are on patient outcomes from the clinical study. These data will be available upon reasonable request to the corresponding author from the GAPVAC-101 study case record forms. Supplementary Tables 1-4 represent raw data and should be used to recapitulate the findings demonstrated in this study. Mass spectrometry data for sequence identification of APVAC warehouse peptides have been deposited at the PeptideAtlas (http://www.peptideatlas.org/) with the dataset identifier PASS01284. mRNA microarray data used for APVAC selection are available at Gene Expression Omnibus (GSE122498). All mutations found in the DNA sequencing are depicted in the manuscript. The uploading of DNA sequencing data with the potential for patient identification was not included in the informed consent that patients gave to the trial; these data will be shared (with identifying information removed) upon reasonable request.
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Extended Data Fig. 8 | TIL isolation and expansion in glioblastoma. A harmonized TIL isolation and expansion protocol for glioblastoma specimens was developed in the preclinical phase of the GAPVAC project (see Methods). a, Cells were expanded in the presence of recombinant human IL-2 at three concentrations. One centre also performed expansion of melanoma and oropharyngeal TILs for comparison. The number of independent tumours compared across laboratories (preclinical samples) are shown in brackets. Data are mean, s.e.m. and individual values for each cell subset. b, Expansion of glioma TILs in the presence or absence of the anti-CD3 antibody OKT3. Indicated number of pieces of tumour obtained from three patients with glioblastoma (outside the GAPVAC-101 trial) were cut in fragments and transferred into 24-well plates with one fragment per well. Fragments were cultured in the absence or presence of 30 ng ml −1 anti-CD3 antibody (OKT3). Expanded cells were collected at the indicated days and subjected to phenotyping by flow cytometry.
Percentages of total CD3
+ , CD4 + and CD8 + T cells and total cell yield are indicated. c, Compositions of TIL cultures derived at one centre from four different patients (6, 7, 8 and 9) The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
Clinical data collection and management was carried out using SAS (version 9.3; SAS Institute, Cary, NC) after double-data entry from a paper CRF. Ex vivo multimer data, pan-ICS and ex vivo ICS data were acquired on a BD LSRII SORP flow cytometer. ELISpot data were acquired with an ImmunoSpot Series 6 ELISpot Reader (C.T.L. Europe, Germany). TIL functional data (flow cytometry) were acquired on an LSR Fortessa SORP equipped with Diva v6.1.2. Treg flow cytometer data were collected on a BD FACSCanto II and analysed using FlowJo software version 10. MS data have been acquired on an Orbitrap Velos and Orbitrap fusion (ThermoFisher). RNA microarray data were acquired by Affymetrix Human Genome (HG) U133 Plus 2.0 oligonucleotide microarrays using an Affymetrix GeneChip Scanner 3000.
Data analysis
Where applicable, data were reported as the median (indicating the range from minimum to maximum value occurred) and arithmetic mean ± standard deviation, as specified (R software package, 3.4.1). Dichotomous variables were evaluated by Fisher's exact test while continuous variables were compared by two-sided t test or Mann-Whitney U test, as indicated. OS and PFS (both calculated from primary tumour diagnosis) were assessed by Kaplan-Meier analysis using Prism 7 (GraphPad Software Inc., CA). An independent data safety monitoring board oversaw the study. Mutation analysis used a software pipeline employing: bwa, bowtie, Immune Epitope Database (IEDB) T-cell prediction tools (version 2.5, IEDB-recommended mode), primer3 software, BLAT. Patient PBMC were limited in this study. If not stated otherwise and owing to limited sample availability, immune response assessments could only be performed once and were not repeated. As detailed in the sections for ex vivo 2D multimer, ex vivo ICS and pan-ICS, various internal and external controls were included and per assay type, all patient assays were done with the same batches of critical reagents (e.g. staining antibodies). Further, all patient assays were performed according to detailed standard operating procedures.
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Ex vivo multimer, and ICS, pan-ICS data,Treg flow cytometer data and TIL functional data were analysed using FlowJo software version 10 (Tree Star, Ashland, USA). LC-MS/MS data were acquired on an Orbitrap Velos or Orbitrap Fusion (Thermo Scientific). mRNA expression microarray data was evaluated by the Affymetrix GeneChip Command Console (AGCC) software.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The authors declare that [the/all other] data supporting the findings of this study are available within the paper [and its supplementary information files]. The data will also be publicly available at the Consortium's homepage (www.gapvac.eu). This is our own policy and following the EU grant requirements.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
For the phase I safety question 3+3 patients would have been sufficient. As the trial aimed at showing feasibility and biological mechansims of action (immunogenicity), we calculated 15 evaluable patients to be sufficient to claim feasibility and to generate a meaningful dataset based on immunogenicity as below: Prospectively and based on previous experience with the off-the-shelf vaccines IMA901 and IMA910 heading for a minimal multi-TUMAP response rate of 40% was considered a reasonable target for the personalized APVAC approach. Calculating with 15 patients evaluable for APVAC1 class I peptides and assuming an observed multi-TUMAP responder rate of 67% (10/15 patients; CI0.95: 38-88%), the probability to see that effect if the true multi-TUMAP response rate really is equal to the target value of 40% would be p=0.061 (two-sided exact binomial test; R software package, version 3.0.2), i.e. a true multi-TUMAP responder rate greater than 40% would be very likely (probability 93.9%).
In the data analysis, the true multi-TUMAP responder rate was much higher. Thus, this endpoint was clearly met, justifying also the set sample size.
Data exclusions No data were excluded, but patient screened and tested for the trial did not necessarily reach the stage of treatment as detailed in Suppl. 
Replication
All clinical data derive their relevance from the treatment of multiple patients; we deemed 16 patients included into the trial as sufficient to show feasibility. Replication of analysis of patient samples was in most cases not possible due to limited amount of patient specimens. Methods for analysis of patient samples where standardized and highly controlled (e.g. immune response analysis, NGS) according to accepted standards in the field. Where applicable, number of replicates are indicated. Variation has been adressed by the number of patients.
Randomization
The trial aims at showing biological effects, not superiority over a standard. Given the immune monitoring being the main outcome, these data would not benefit from randomization but negative controls, which are included. Variation has been adressed by the number of patients.
Blinding
The clinical evaluation regarding toxicity was non-blinded. Blinding would not enhance awareness in this phase I trial. The clinical efficacy data (MRI) were assessed centrally and blinded for the stage and kind of therapy. The translational/immune monitoring data were blinded to any clinical treatment.
Reporting for specific materials, systems and methods
